Navigation Links
Adeona Reports Second Quarter 2011 Financial Results
Date:8/15/2011

cly disclosed in May 2011, Meda stated that flupirtine for fibromyalgia was in Phase II development.

Amyotrophic Lateral Sclerosis (ALS)

  • In June 2011, we announced plans to sponsor a Phase IIb clinical trial for patients suffering from ALS, also known as Lou Gehrig's disease. The trial is intended to evaluate the safety and efficacy of our proprietary drug candidates, AEN-100, a gastroretentive, sustained-release zinc-based tablet, and AEN-200, a copper tablet, in a multi-center, double-blind, placebo-controlled clinical trial in ALS patients.

  • The trial will be led by the neurological team at the PNA Center for Neurological Research (Center) and is based on the Center's hypothesis that giving high doses of zinc to ALS patients may decrease the amount of toxicity from unbound glutamate and prevent neurotoxicity.

Mild to Moderate Alzheimer's Disease

  • After conducting further analyses of the results presented in April 2011 from the clinical study evaluating our medical food, reaZin™, an apparent cognitive benefit was observed in older patients. Preparations are underway to conduct a larger clinical study of AEN-100 (our zinc-based drug candidate) under an Investigational New Drug (IND) application in patients with mild to moderate Alzheimer's disease who are age 70 and over. It is anticipated that the clinical study will enroll just over 100 patients and that the evaluation period will be at least 12 months.

  • Our plans are to develop our proprietary zinc-based tablet, AEN-100, as a drug in parallel with making reaZin available as a medical food. AEN-100 is a proprietary, once-daily, gastroretentive, sustained-release, oral tablet formulation of zinc.

Near-Term Product Development Programs'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Adeona to Host Second Quarter 2011 Investor Conference Call
2. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
3. Adeona Reports 1st Quarter 2011 Financial Results
4. Adeona to Host First Quarter 2011 Investor Conference Call
5. Adeona Executes Manufacturing and Supply Agreement with TG United for reaZin™
6. Adeonas Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper
7. Adeona to Host Conference Call
8. Adeona to Raise $3.5 Million in Registered Direct Offering
9. Adeona Reports 2010 Year End Financial Results
10. Adeona to Host 2010 Year End Investor Conference Call
11. Adeonas Multiple Sclerosis Trial Receives $409,426 Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 Leading events organizer UBM Live ... the seventh year to São Paulo, Brazil ... 2014. The event will co-locate with Food Ingredients South America ... meeting point for the pharmaceutical industry.      (Logo: ... pharmaceutical sales are now exploring the South America ...
(Date:7/24/2014)... July 24, 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... on the development and commercialization of innovative therapies for ... the PDUFA date for Zalviso remains July 27, 2014.  ... circulated online stating the Food and Drug Administration (FDA) ... has been no notification to the company from the ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... 2011 Orexigen ® Therapeutics, Inc. (Nasdaq: OREX ... Securities Healthcare Conference in New York. The presentation is scheduled for ... listen to the live webcast or a replay of the presentation, ... at www.orexigen.com . A replay will be available for 14 ...
... MONMOUTH JUNCTION, N.J., Sept. 26, 2011 Insmed Incorporated (Nasdaq ... President and CEO of Insmed, will be presenting a corporate ... Wednesday, September 28, 2011, at 11:30 AM ET, in New ... available on Insmed,s website, http://www.insmed.com .  The webcast will ...
Cached Medicine Technology:Insmed to Present at Sixth Annual JMP Securities Healthcare Conference 2
(Date:7/27/2014)... July 28, 2014 Recently, Wdsshop.de, a reliable ... new collection of fabulous prom dresses on its ... discounted prices, up to 58% off. , “We are pleased ... product line. They are specially created for those who are ... is great and vivid in style. I think our clients ...
(Date:7/27/2014)... systematic analysis of hepatitis E virus (HEV) transmission by ... in England have HEV in their plasma. The findings, ... 1200 HEV-containing blood components (eg, red cells, platelets, and ... year in England. , The study retrospectively screened ... England between Oct, 2012 and Sept, 2013 for HEV ...
(Date:7/27/2014)... Albany, New York (PRWEB) July 27, 2014 ... Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative ... Share, Growth, Trends and Forecast, 2013-2019" the global endoscopy ... 2012 and is expected to grow at a CAGR ... estimated value of USD 36.9 billion in 2019. , ...
(Date:7/27/2014)... Vancouver, BC (PRWEB) July 27, 2014 ... have recently announced their demonstration depicting the hamstring release ... Backs in Action Wellness Center in Vancouver and have ... The hamstring release procedure was carried out by the ... The purpose of the exercise is to release tight ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel ... HCVs), Market Type (OE & Aftermarket), Filter Type (Oil ... - Industry Trends & Forecast to 2018”, defines and ... with analysis and forecasting of the global volume and ... to reach a revenue of $6.1 billion in 2018, ...
Breaking Medicine News(10 mins):Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Renowned Vancouver Chiropractors Demonstrates Hamstring Release in Vancouver, BC 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5
... CardioCareLive, the world,s largest live online cardiology congress ... Medicine, today announced three new complimentary Continuing Medical ... days on Tuesday June 28th and Wednesday June ... and internal medicine and family care physicians in ...
... latest episode in the American Chemical Society,s (ACS) ... focuses on new blood test that can quickly ... bacterium that,s become a global threat, significantly improving ... Staphylococcus aureus, or simply MRSA. The podcast explains ...
... 24 (HealthDay News) -- Rain-making bacteria may shed some ... the Earth,s precipitation cycle, new research shows. ... meeting of the American Society for Microbiology in New ... of hailstones, suggesting that airborne microorganisms may trigger precipitation, ...
... knowledge of tuberculosisas well as in the practices, programs ... with human immunodeficiency virus (HIV)the spread of multidrug-resistant (MDR) ... community. Research in the June issue of The ... use of 18F-FDG positron emission tomography (PET) scans can ...
... MA Electronic medical records (EMRs) have been in use ... utilization in recent years, due in part to research supporting ... become a standard in medical care, there is a need ... be refined. A group of researchers from Brigham and Women,s ...
... you may want to think twice before shooting hundreds of ... study from MIT neuroscientists shows that the most memorable photos ... and human-scale objects. Landscapes? They may be beautiful, but they ... are not the same," says MIT graduate student Phillip Isola, ...
Cached Medicine News:Health News:CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive 2Health News:CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive 3Health News:New American Chemical Society podcast: Fast test to diagnose MRSA infections 2Health News:Airborne Germs May Spur Rain, Snow, Hail 2Health News:PET scans predict effectiveness of treatment for multidrug-resistant tuberculosis in HIV patients 2Health News:MIT research: What makes an image memorable? 2Health News:MIT research: What makes an image memorable? 3
... NPB-290 and NPB-295 Pulse Oximeters are ... accuracy, reliability and proven signal processing ... perfused patients. Equipped with Oxismart Advanced ... these pulse oximeters identify electronic and ...
... Oximeter with Oxismart XL Advanced Signal Processing ... nonspecific noise to find the pulse and ... rate values. , ,The N395 monitor ... a breakthrough in clinician-programmable alarm sensitivity for ...
The Model 5340 is intended for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
The Model 5305 is a hand-held, portable, lightweight pulse oximeter designed for spot checking. It has a NiCad rechargeable battery....
Medicine Products: